Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly where on that website is BioHeart mentioned?
Buy, hold, accumulate.
http://www.barchart.com/opinions/stocks/ACTC
100% buy from one day to the next.
Yes they do according to some PRs. Also it is my opinion that the revenue is already coming in.
I've been spotting a slight trend in both stocks.
No sinking ships?? Interesting.
Excellent post.
Both companies are after the same money plain and simple. To say AMR-001 could potentially be worth billions is to say Myocell could be worth billions. That was the point. The post was meant for those who could see the big picture.
Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack. The procedure involves a physician removing a small amount of muscle from the patient's thigh. From this muscle specimen, muscle stem cells (also called myoblasts) are then isolated, expanded using Bioheart's proprietary cell-culturing process, and injected directly into the scar tissue of the patient's heart. The cells are delivered by an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The muscle stem cells populate the regions of scar tissue and are intended to improve cardiac function by helping the heart muscle beat more efficiently.
The market is huge, and BioHeart is leading the way.
http://wallstcheatsheet.com/business/stock-news/neostem-a-potential-blockbuster-for-investors.html/?a=viewall
The Billion Dollar Drug
AMR-001 is a bone marrow derived stem cell treatment designed to prevent major adverse cardiac events following acute myocardial infarction (heart attacks.) The potential market for AMR-001 is simply huge. According to Million Hearts, 2,200 people die from cardiovascular diseases every day. That is 800,000 a year or 1 in every 3 deaths. The cost of this has been estimated to be in excess of $312b per year.
Of the 800,000 events each year, 20 percent or approximately 160,000 patients have a ST-Elevation MI (STEMI), resulting in a reduced Left Ventricular Ejection Fraction (LVEF) of less than 50 percent. What this essentially means is that the heart attack was big enough and the heart so damaged that the remaining heart muscle could not compensate for the damaged heart tissues and, over time, the heart failed. It is these patients that are at significant risk for more adverse events including congestive heart failure, re-current heart attacks and/or premature death. It is also these patients that are a large part of the growing healthcare costs for cardiac events because many times they have repeated cardiac events that must be treated. This is the population that AMR-001 is targeting and it represents a potential market of over $1.2 billion annually for AMR–001 according to NBS.
AMR-001 is currently in Phase 2 trials with results expected in the third-quarter of this year. The Phase 2 trial is being conducted at 60 medical centers across the United States with 160 patients. The primary endpoint of the trial is a change in cardiac perfusion (RTSS by SPECT) from the baseline to 6 months. NBS is also currently looking to initiate filings for a Phase 1b/2a for chronic heart failure, a potential market of 23 million patients and billions in potential revenue.
Maybe this month is our last opportunity to load up at these prices. IMO
I recently re-read all the blogs available from last year and the most recent one in January... I can't help but understand the slowly but steady approach to success that BioHeart is taking. All signs IMO point to 2014 being the year that we finally emerge on the scene as RECOGNIZED leaders in the field of regenerative medicine. There is a big difference between people knowing BioHeart exists... And not. One look at the current pps will prove it.
I also took the time to re-read a few key PRs and IMO BioHeart is ready to announce key revenue streams. Of course this is just speculation based on DD... Which makes it speculation of the best kind. GLTA
Ask us today about STEM CELL BANKING!
An Additional Service for your patients
& an Additional Revenue Stream for you!
Why Bank Stem Cells with BIOHEART?
Bioheart provides cell storage services for stem cell patients in their state-of-the-art, FDA registered tissue bank
Bioheart is an international biotechnology company focused on providing the most comprehensive medical solutions
Bioheart offers a full range of regenerative medicine therapies to patients worldwide
Main Reasons to Bank Cells NOW?
Provides your patient with the peace of mind that he or she will have healthy stem cells available for any potential future illness or injury
Banking stem cells now will provide the patient with the maximum amount of healthy, young stem cells
Your patient would not have to to undergo another surgical tissue harvest in the future
How Does Bioheart
Bank Stem Cells?
LEARN MORE TODAY!
Banking@bioheartinc.com
Phone: 954.835.1500
Fax: 954.845.9976
www.bioheartinc.com
Anyone get the BioHeart news letter on Monday??
Which trials could they be referring to here?
http://www.miamiherald.com/2014/02/26/3961125/university-of-miami-researchers.html
That SA article that was released today is a load of crap IMO.
Yes, excited indeed. I think a steady climb to the 2 and a half cent level IMO before the 10K. Then from there after, who knows. It's up to the news to decide.
Thanks Gsdubb.
I thought they were using the J&J catheter (Johnson & Johnson). Someone correct me if I'm wrong please.
That is a nice and true post about Advanced Cell Technology. The past is in itself and the future is bright enough to SEE.
Nice and also true post about the good Dr. Lanza.
What am I looking for on that site??
Forgive my ignorance. Are we due for quarterly or annual financials?? Or both...
We need an update from mike ASAP.
By chance is it ACTC that is making the injections to your grandmothers right eye?
Nice post, that's the only way to not get deleted. Writing nice posts like that. Go actc! The POS company
Lol... Slap that a$k. Come on guys this isn't Instagram.
BHRT in my opinion is releasing small bits of information one dose at a time before they drop the bomb! Connect the dots here, it is my opinion that we've got a winner. GLTA
Thank you for posting this. Cannot wait for the topline data in the New England Journal of Medicine
Thank you for the clarification. I do remember reading the PR where the FDA put the temporary hold. I appreciate you putting it in terms that are more understandable.
I also want to add that it seems as though many of BioHeart PRs from last year seem to explain BioHeart positioning itself with different revenue streams... Science to the side.
I believe this is the reason for our upward trend.
http://clinicaltrials.gov/ct2/show/NCT00526253?term=bioheart+inc&rank=3
Estimated Enrollment: 170
Study Start Date: September 2007
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
I agree.
Here's the PR for that... Looks like their success will be ours as well IMO. http://ih.advfn.com/p.php?pid=nmona&article=59859040
Doesn't bioheart have dome kind of agreement with the company if I'm not mistaken?
http://m.digitaljournal.com/pr/1720392
The fact that Lanza featured on this mainstream introduction of stem cells to the masses and mentioned that he was "in clinical trials to treat blindness using retinal cells"... And the narrator introduced him stating that he was already using stem cells to help patients regenerate damaged body party, tells me that phase 1 went exceptional. I am looking forward to the TLD in the NEJM.
"Serious or life threatening". Someone going blind is an extremely "serious" condition. Thanks for the positive DD. Breakthrough status seems to be looking even more probable.